Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Staging
103 results:
1. Study on Targeted Drugs for Non-small cell NSCLC with PD-1PD-L1 Signaling Pathway.
Cao X
Stud Health Technol Inform; 2023 Nov; 308():562-567. PubMed ID: 38007784
[TBL] [Abstract] [Full Text] [Related]
2. Perioperative Durvalumab for Resectable Non-small-cell lung cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract] [Full Text] [Related]
3. A real-world study comparing perioperative chemotherapy and egfr-tyrosine kinase inhibitors for treatment of resected stage III egfr-mutant adenocarcinoma.
Chen CL; Wang ST; Liao WC; Chen CH; Tu CY; Hsia TC; Cheng WC; Chen HJ
BMC Cancer; 2023 Sep; 23(1):847. PubMed ID: 37697233
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
5. Clinical characteristics of miliary pulmonary metastases in non-small cell lung cancer.
Choi H; Im Y; Jeong BH; Lee K; Kim H; Um SW
Thorac Cancer; 2023 Aug; 14(22):2168-2176. PubMed ID: 37337934
[TBL] [Abstract] [Full Text] [Related]
6. [A Case of Multiple Brain Metastases after Surgery for lung cancer Successfully Treated with Osimertinib].
Takeuchi K; Hayakawa N; Ouchi M
Gan To Kagaku Ryoho; 2023 May; 50(5):631-633. PubMed ID: 37218327
[TBL] [Abstract] [Full Text] [Related]
7. The role of brain radiotherapy for egfr- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Nardone V; Romeo C; D'Ippolito E; Pastina P; D'Apolito M; Pirtoli L; Caraglia M; Mutti L; Bianco G; Falzea AC; Giannicola R; Giordano A; Tagliaferri P; Vinciguerra C; Desideri I; Loi M; Reginelli A; Cappabianca S; Tassone P; Correale P
Radiol Med; 2023 Mar; 128(3):316-329. PubMed ID: 36786970
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Associations of
Chang SL; Yang PJ; Lin YY; Jiang YJ; Liu PI; Huang CL; Yang SF; Tang CH
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429891
[TBL] [Abstract] [Full Text] [Related]
9. A novel egfr exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R
ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454
[TBL] [Abstract] [Full Text] [Related]
11. IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING egfr and ALK MUTATION in PATIENTS with NON-small cell lung cancer.
Agüloğlu N; Aksu A; Akyol M; Katgı N; Doksöz TÇ
Nuklearmedizin; 2022 Dec; 61(6):433-439. PubMed ID: 35977671
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.
Jang SH; Lee DY; Jeong J; Choi WI
Korean J Intern Med; 2022 Jul; 37(4):811-820. PubMed ID: 35811369
[TBL] [Abstract] [Full Text] [Related]
13. Delineating and sparing functional nephrons for radiotherapy in the case of lymphoma with polycystic kidney disease.
Gurusamy VM; Chandramouli SH; Usman M; Divakar SR; Hammoud RW; Al-Hammadi N
Cancer Treat Res Commun; 2022; 31():100566. PubMed ID: 35487053
[TBL] [Abstract] [Full Text] [Related]
14. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-egfr-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
[No Abstract] [Full Text] [Related]
15. Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC-A retrospective single-center experience.
Karadzovska-Kotevska M; Brunnström H; Kosieradzki J; Ek L; Estberg C; Staaf J; Barath S; Planck M
PLoS One; 2022; 17(2):e0263342. PubMed ID: 35108331
[TBL] [Abstract] [Full Text] [Related]
16. Rhomboid domain containing 1 promotes the growth of non-small cell lung cancer through the activation of egfr and regulation of the BIK-mediated apoptosis.
Xu ZY; Li X; Yao RH; Yang LM; Peng H; Ren WJ; Lu H; Wang P
Neoplasma; 2022 Mar; 69(2):311-320. PubMed ID: 34962825
[TBL] [Abstract] [Full Text] [Related]
17. Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
Yang Y; Zhang T; Zhou Z; Liang J; Chen D; Feng Q; Xiao Z; Hui Z; Lv J; Deng L; Wang X; Wang W; Wang J; Liu W; Zhai Y; Wang J; Bi N; Wang L
Thorac Cancer; 2022 Feb; 13(3):296-307. PubMed ID: 34927371
[TBL] [Abstract] [Full Text] [Related]
18. Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non-small cell lung cancer.
Zhong Y; She Y; Deng J; Chen S; Wang T; Yang M; Ma M; Song Y; Qi H; Wang Y; Shi J; Wu C; Xie D; Chen C;
Radiology; 2022 Jan; 302(1):200-211. PubMed ID: 34698568
[TBL] [Abstract] [Full Text] [Related]
19. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small cell lung cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract] [Full Text] [Related]
20. egfr analysis on scrapings from cytology smears in lung carcinoma, an effective alternative to testing on trucut biopsies.
Mohan AA; Vallonthaiel AG; Nambiar A; Ariyannur P; Joy RA; Thelakkattusserry SK; Vikkath N; Joseph T; Mehta A; Perathur A
Diagn Cytopathol; 2021 Oct; 49(10):1155-1163. PubMed ID: 34432954
[TBL] [Abstract] [Full Text] [Related]
[Next]
